Clinical Trials · NCT03899402
Triple Therapy in T1DM
- Phase
- Phase 2/Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- State University of New York at Buffalo
- Enrollment
- 78
- Start date
- May 2019
- Locations
- 1 site, United States
- Primary endpoint
- Change in HbA1c following dapagliflozin